Target intelligence / Profile preview

Chondroitin sulfate E (CS-E)

Target
CS-E
Molecular classification
Glycosaminoglycan, Polysaccharide, Carbohydrate, Other
01

Overview

Chondroitin sulfate E (CS-E) is a highly sulfated glycosaminoglycan characterized by a repeating disaccharide unit of D-glucuronic acid and N-acetyl-D-galactosamine, with sulfation at both the C4 and C6 positions of the galactosamine residue. It is a key component of the extracellular matrix and cell surface proteoglycans, playing critical roles in cell adhesion, migration, angiogenesis, and signal transduction. CS-E acts as a functional ligand or co-receptor for various growth factors, chemokines, and cell surface receptors, such as midkine, pleiotrophin, VEGF, and contactin-1. In disease states, CS-E is upregulated in several cancers (including prostate, breast, and ovarian cancers), where it promotes tumor progression, metastasis, and therapeutic resistance by activating oncogenic pathways like IL-6/STAT3 and Wnt/beta-catenin. It is also implicated in inflammatory conditions like osteoarthritis and rheumatoid arthritis, as well as the inhibition of neural repair following central nervous system injury. Therapeutic strategies targeting CS-E include small-molecule inhibitors of its biosynthetic enzyme CHST15 (such as Chst15-IN-1), enzymatic degradation using chondroitinase ABC, and specific monoclonal antibodies (such as GD3G7, E-12C, and E-18H) to neutralize its activity or serve as diagnostic biomarkers.

Other names
Chondroitin-4,6-sulfateOversulfated chondroitin sulfate EChondroitin sulfate E (CS-E)
02

Mechanism of action

Inhibition of CHST15 (N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase) to reduce CS-E biosynthesis, enzymatic degradation of chondroitin sulfate chains, or monoclonal antibody binding and neutralization of CS-E.

03

Biological functions

Cell adhesionCell migrationSignal transductionAngiogenesisImmune responseOther
04

Disease associations

CancerInflammationNeurodegenerative diseaseOther
05

Safety considerations

Potential off-target effects on normal tissues expressing low levels of CS-EImpairment of normal tissue repair or neuroplasticityBleeding risksImmunogenicity of antibody-based therapies or bacterial enzymes
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

CHST15 expressionGalNAc4S-6OST expressionCS-E expression levels

Beyond the preview

Go deeper on Chondroitin sulfate E (CS-E).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chondroitin sulfate E (CS-E).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call